Trial Profile
A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Diverticulitis
- Focus Therapeutic Use
- Acronyms PREVENT1
- Sponsors Shire
- 01 Oct 2014 New trial record